Novel agents targeting the IGF-1R/PI3K pathway impair cell proliferation and survival in subsets of medulloblastoma and neuroblastoma

Wojtalla, Anna; Salm, Fabiana; Christiansen, Ditte G.; Cremona, Tiziana; Cwiek, Paulina; Shalaby, Tarek; Gross, Nicole; Grotzer, Michael A.; Arcaro, Alexandre (2012). Novel agents targeting the IGF-1R/PI3K pathway impair cell proliferation and survival in subsets of medulloblastoma and neuroblastoma. PLoS ONE, 7(10), e47109. Lawrence, Kans.: Public Library of Science 10.1371/journal.pone.0047109

[img]
Preview
Text
journal.pone.0047109.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (1MB) | Preview

The receptor tyrosine kinase (RTK)/phosphoinositide 3-kinase (PI3K) pathway is fundamental for cancer cell proliferation and is known to be frequently altered and activated in neoplasia, including embryonal tumors. Based on the high frequency of alterations, targeting components of the PI3K signaling pathway is considered to be a promising therapeutic approach for cancer treatment. Here, we have investigated the potential of targeting the axis of the insulin-like growth factor-1 receptor (IGF-1R) and PI3K signaling in two common cancers of childhood: neuroblastoma, the most common extracranial tumor in children and medulloblastoma, the most frequent malignant childhood brain tumor. By treating neuroblastoma and medulloblastoma cells with R1507, a specific humanized monoclonal antibody against the IGF-1R, we could observe cell line-specific responses and in some cases a strong decrease in cell proliferation. In contrast, targeting the PI3K p110α with the specific inhibitor PIK75 resulted in broad anti-proliferative effects in a panel of neuro- and medulloblastoma cell lines. Additionally, sensitization to commonly used chemotherapeutic agents occurred in neuroblastoma cells upon treatment with R1507 or PIK75. Furthermore, by studying the expression and phosphorylation state of IGF-1R/PI3K downstream signaling targets we found down-regulated signaling pathway activation. In addition, apoptosis occurred in embryonal tumor cells after treatment with PIK75 or R1507. Together, our studies demonstrate the potential of targeting the IGF-1R/PI3K signaling axis in embryonal tumors. Hopefully, this knowledge will contribute to the development of urgently required new targeted therapies for embryonal tumors.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Paediatric Medicine
04 Faculty of Medicine > Pre-clinic Human Medicine > Theodor Kocher Institute

UniBE Contributor:

Wojtalla, Anna, Salm, Fabiana, Cremona, Tiziana Patrizia, Arcaro, Alexandre

ISSN:

1932-6203

Publisher:

Public Library of Science

Language:

English

Submitter:

Anette van Dorland

Date Deposited:

04 Oct 2013 14:36

Last Modified:

05 Dec 2022 14:11

Publisher DOI:

10.1371/journal.pone.0047109

PubMed ID:

23056595

Web of Science ID:

000309831500137

BORIS DOI:

10.7892/boris.14682

URI:

https://boris.unibe.ch/id/eprint/14682 (FactScience: 221781)

Actions (login required)

Edit item Edit item
Provide Feedback